Page 5 - Prehevbrio Prehevbri News Today : Breaking News, Live Updates & Top Stories | Vimarsana

VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

PreHevbri® is the only approved 3-antigen hepatitis B vaccine for adults in the Netherlands and Belgium Product to be launched via marketing and distribution partner, Valneva

United statesUnited kingdomPrehevbrio prehevbriJeff baxterEuropean union economic areaCompany quarterly reports on formVaccines incEuropean economic areaEuropean summaryProduct characteristicsPrivate securities litigation reform actAnnual reportQuarterly reports

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering

Approximately $21 million in gross proceeds from underwritten public offering and concurrent registered direct offering add to upfront payment from Brii Biosciences for a combined $33 million to be.

United statesUnited kingdomSankt peterburgPrehevbrio prehevbriNicole andersonBrii biosciencesNewbridge securities corporationCorporate communicationsRaymond james associates incExchange commissionEuropean union economic areaVaccines incCompany quarterly reports on formEquity syndicateSecurities corporationEuropean economic area

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sankt peterburgUnited kingdomUnited statesNicole andersonBrii biosciencesPrehevbrio prehevbriCorporate communicationsExchange commissionRaymond james associates incVaccines incNewbridge securities corporationEquity syndicateCompany quarterly reports on formEuropean union economic areaSecurities corporationRaymond james

VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties

Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region VBI will receive gross proceeds of $15 million in upfront payments, subject to near-term milestone achievements, including an equity investment of approximately $3 million VBI is eligible to receive up to $422 million in additional potential regulatory and commercial milestone payments, plus double-digit royalties

United statesUnited kingdomBrii biosciencesAsia pacificPrehevbrio prehevbriBrii biosciences bioJeff baxterBrii bioZhi hongVaccines incEuropean union economic areaCompany quarterly reports on formOngoing phaseAnnual conferenceAsian pacific associationEuropean economic area

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants

VBI Vaccines Inc. ; class= js-l-obf link link blue

United kingdomUnited statesSankt peterburgPrehevbrio prehevbriEuropean union economic areaEquity syndicateExchange commissionCompany quarterly reports on formRaymond james associates incVaccines incNewbridge securities corporationSecurities corporationRaymond jamesEuropean economic areaSafety informationFull prescribing